AACR 2024: PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine
PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022
LIÈGE, Belgium & GRENOBLE, France--(BUSINESS WIRE)--PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active off-the-shelf cancer vaccine, announces today the completion of its Series B2 round of financing. The company has raised a total of €17.5 million ($20.3M) with Belgian and South-Korean investors.